The GNA Biosolutions GmbH (GNA) won the Disruptive Technology Award at the 70th American Association of Clinical Chemistry (AACC) Conference. The AACC is an annual scientific conference with dedicated booths dedicated to clinical laboratory diagnostics, attracting approximately 50,000 attendees annually and being held this year in Chicago, Illinois.
The AACC "Disruptive Technology Award" recognizes innovative diagnostic procedures that improve patient care through increased diagnostic quality or easier access to high-performance diagnostic procedures. In addition to convincing the jury, GNA Biosolutions, based in the Innovation and Start-up Center for Biotechnology (IZB) in Martinsried near Munich, also impressed the expert audience at the awards ceremony in Chicago and received the Audience Award for Best Technology. GNA presented data on its proprietary "Pulse Controlled Amplification" (PCA) technology at the AACC. This technology, developed by GNA, enables extremely fast molecular diagnostic workflows (from patient sample to result in 15 minutes or less), even with difficult clinical material such as blood.
Fight against multi-resistant germs
At the end of 2017, GNA launched its first instrument based on PCA technology (the Pharos V8). GNA is currently developing a highly mobile and cost-effective platform for point-of-care molecular diagnostic detection of infectious diseases in the POC setting. The test pipeline for the planned POC platform, which will be operable even by untrained personnel, primarily targets various multidrug-resistant pathogens, which are clinically highly relevant causes of hospital-acquired infections, as well as antibiotic-resistant tuberculosis (MDR-TB). According to the World Health Organization, multidrug-resistant pathogens are considered a major challenge and a significant threat to global health.
"We are very honored to receive the AACC's Disruptive Technology Award."
said GNA Biosolutions Co-Founder and Managing Director, Dr. Lars Ullerich, on Monday evening in Chicago.
"Being recognized for PCA technology fills our entire team with great pride. We are committed to revolutionizing the point-of-care market with our technology."
To explore further application areas, GNA is entering into strategic partnerships with companies in other areas of DNA analysis. These companies benefit from the unique potential of PCA technology, which can be used both for individual patient samples in the point-of-care (POC) setting and for high-throughput applications in central laboratories, significantly accelerating the entire workflow from sample to result.
